NUCALA VIDEO LIBRARY

Watch videos about severe eosinophilic asthma (SEA), the NUCALA mechanism of action (MOA), or dosing & administration instructions.

Hear from your peers about NUCALA

NUCALA efficacy & safety in SEA

In this video, an expert in pulmonology and critical care medicine describes how NUCALA can help patients with severe eosinophilic asthma (SEA).

GO TO VIDEO
Video thumbnail: NUCALA (mepolizumab) efficacy and safety for patients with severe eosinophilic asthma with Dr. Yaron Goldman

An anti-IL-5 to target eosinophils

In this video, learn about NUCALA from specialists in immunology, pulmonology, critical care medicine, and otolaryngology.

GO TO VIDEO
Video thumbnail: An anti-IL-5 approved for select eosinophil-driven diseases

View the NUCALA MOA

Mechanism of action

Learn about the NUCALA (mepolizumab) mechanism of action (MOA) in asthma.

GO TO VIDEO
Video thumbnail: Illustration of the mechanism of action (MOA) of NUCALA (mepolizumab) in asthma

NUCALA dosing & administration videos

Video thumbnail: How to use the NUCALA Autoinjector at home

How to use the NUCALA Autoinjector at home (for ages 12+)

In this video, your appropriate patients can learn how to administer NUCALA at home using the NUCALA Autoinjector.

GO TO VIDEO
Video thumbnail: NUCALA Autoinjector patient perspective

NUCALA Autoinjector: a patient perspective

What could the Autoinjector mean to your patients? Watch now and find out.

GO TO VIDEO
Video thumbnail: How to use the NUCALA 100 mg/mL prefilled syringe

How to use the NUCALA 100 mg/mL prefilled syringe (for ages 12+)

A detailed guide to show your patients how to use this prefilled syringe at home for their NUCALA injection.

GO TO VIDEO
Video thumbnail: How to use the NUCALA 40 mg/mL prefilled syringe

How to use the NUCALA 40 mg/0.4 mL prefilled syringe (for ages 6-11)

For pediatric patients ages 6-11, this prefilled syringe can be administered by an HCP in the office or by a caregiver at home.

GO TO VIDEO
Video thumbnail: Manual reconstitution instructions for 1 vial of NUCALA

MANUAL reconstitution instructions for 1 vial of NUCALA

For in-office administration of NUCALA, watch this video to learn how to reconstitute NUCALA manually.

GO TO VIDEO
Video thumbnail: Mechanical reconstitution instructions for 1 vial of NUCALA

MECHANICAL reconstitution instructions for 1 vial of NUCALA

For in-office administration of NUCALA, watch this video to learn how to reconstitute NUCALA mechanically.

GO TO VIDEO

INDICATIONS & IMPORTANT SAFETY INFO

INDICATIONS

IMPORTANT SAFETY INFORMATION

INDICATIONS

NUCALA is indicated for the: 

  • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids.
  • add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm.
  • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. 

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to mepolizumab or excipients.

 

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). Discontinue if a hypersensitivity reaction occurs.

 

Acute Symptoms of Asthma or COPD or Acute Deteriorating Disease

NUCALA should not be used to treat acute symptoms or acute exacerbations of asthma or COPD, or acute bronchospasm.

 

Opportunistic Infections: Herpes Zoster

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

 

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

 

Parasitic (Helminth) Infection

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

 

ADVERSE REACTIONS

Most common adverse reactions (≥5%):

  • Severe asthma trials: headache, injection site reaction, back pain, fatigue
  • CRSwNP trial: oropharyngeal pain, arthralgia
  • COPD trials: back pain, diarrhea, cough
  • EGPA and HES trials (300 mg of NUCALA): most common adverse reactions were similar to severe asthma

Systemic reactions, including hypersensitivity, occurred in clinical trials in patients receiving NUCALA. Manifestations included rash, pruritus, headache, myalgia, flushing, urticaria, erythema, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, stridor, angioedema, and multifocal skin reaction. A majority of systemic reactions were experienced the day of dosing.

 

USE IN SPECIFIC POPULATIONS

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

 

Please see full Prescribing Information and Patient Information for NUCALA.

PMUS-MPLWCNT240085 May 2025

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or
FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.